Medical AI

With its world-first gastric cancer drug heading for approval, Innovent Biologics isn't just offering new hope—it's executing a masterclass in strategic leverage.

Parnell's new Sevoflurane offering is more than a product line extension; it's a strategic move to become a one-stop-shop for veterinary anesthesia.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

A new AI can detect Parkinson's progression where the current gold standard fails. In a stunning validation, the study was led by the very scientists who created the old method.

As Alexandria grapples with a documented mental health crisis, a new clinic introduces advanced TMS and ketamine therapies to a region burdened by long waits.

CHIGEE’s new XR-1 dash cam disappears into the bike, trading screens for voice alerts. We analyze if this minimalist approach is the future of rider safety.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

Precision Cardiovascular adds serial entrepreneur Brian Fahey to its board, signaling a push to commercialize its implantable SAW sensor and AI platform.

A new partnership embeds quantum-resilient security into AI robotics, signaling a strategic maneuver to preempt future threats and dominate a new era of compliance.

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

As Rise Therapeutics advances its oral drug R-2487, it’s not just developing another pill. It’s testing a radical new idea: resetting the immune system.

Mindray's new Hepatus-Series goes beyond a simple product launch, integrating AI-driven elastography to transform GI diagnostics and challenging market norms.

As one major allergy drug exits, a biotech startup is testing a new path: a microneedle skin stamp. Is this the future of allergy treatment?

An Israeli-American tech firm just put AI eyes on a US Black Hawk, pioneering a new era of visual predictive maintenance that could transform aviation safety.

Medscape's new AI symposium aims to guide hematologists through an ethical revolution, promising to enhance, not replace, clinical expertise. Is this the future?

The Dallas Cowboys are using a new device to build muscle. It’s part of a high-stakes trend where technology is redefining athlete recovery and longevity.

Inipharm's INI-822 study leverages genetic insights for an oral MASH therapy, challenging injectable rivals and offering new hope for high-risk patients.

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

With dual FDA clearances secured, Rhythm AI appoints serial acquirer Mike Dineen as CEO, signaling a strategic pivot from innovation to market conquest.